Literature DB >> 25183049

Expression and clinical significance of IMP3 in microdissected premalignant and malignant pancreatic lesions.

B-J Wang1, L Wang, S-Y Yang, Z-J Liu.   

Abstract

INTRODUCTION: Insulin-like growth factor 2 (IGF-2) mRNA-binding protein 3 (IMP3) is overexpressed in pancreatic cancer, while remaining undetectable in the normal pancreas, indicating its important role in pancreatic cancer pathogenesis. The role of IMP3 in pancreatic carcinogenesis has not been fully understood. The main goal of this study was to probe the expression profile of IMP3 in different stages of pancreatic ductal adenocarcinoma (PDAC) development, and evaluate their prognostic significance in PDAC patients.
MATERIALS AND METHODS: We used quantitative real-time RT-PCR combined manual microdissection to precisely detect IMP3 expression in 97 microdissected foci from 50 patients with PDAC. Nonparametric test, Log-rank test and Cox regression analysis were used to evaluate the clinical significance of DNMTs expression.
RESULTS: Expression of IMP3 increased from normal duct to pancreatic intraductal neoplasia and to PDAC. IMP3 mRNA expression statistically correlated with TNM staging. Univariate analysis showed that high level of IMP3 expression, tumor differentiation, TNM staging and alcohol consumption were statistically significant risk factors. Multivariate analysis showed that high level of IMP3 expression and tumor differentiation were statistically significant independent poor prognostic factors.
CONCLUSIONS: These results suggested that pancreatic carcinogenesis involves an increased IMP3 mRNA expression, and it may become valuable diagnostic and prognostic markers as well as potential therapeutic targets for pancreatic cancer.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25183049     DOI: 10.1007/s12094-014-1216-4

Source DB:  PubMed          Journal:  Clin Transl Oncol        ISSN: 1699-048X            Impact factor:   3.405


  27 in total

1.  Association of increased DNA methyltransferase expression with carcinogenesis and poor prognosis in pancreatic ductal adenocarcinoma.

Authors:  Jing-Jing Zhang; Yi Zhu; Yan Zhu; Jun-Li Wu; Wen-Biao Liang; Rong Zhu; Ze-Kuan Xu; Qing Du; Yi Miao
Journal:  Clin Transl Oncol       Date:  2012-02       Impact factor: 3.405

2.  Analysis of RNA-binding protein IMP3 to predict metastasis and prognosis of renal-cell carcinoma: a retrospective study.

Authors:  Zhong Jiang; Peigou G Chu; Bruce A Woda; Kenneth L Rock; Qin Liu; Chung-Cheng Hsieh; Cuizhen Li; Wengang Chen; Hai Ou Duan; Scott McDougal; Chin-Lee Wu
Journal:  Lancet Oncol       Date:  2006-07       Impact factor: 41.316

3.  A family of insulin-like growth factor II mRNA-binding proteins represses translation in late development.

Authors:  J Nielsen; J Christiansen; J Lykke-Andersen; A H Johnsen; U M Wewer; F C Nielsen
Journal:  Mol Cell Biol       Date:  1999-02       Impact factor: 4.272

4.  Diagnostic value of immunohistochemical IMP3 expression in core needle biopsies of pancreatic ductal adenocarcinoma.

Authors:  David Lukas Wachter; Anne Schlabrakowski; Josef Hoegel; Glen Kristiansen; Arndt Hartmann; Marc-Oliver Riener
Journal:  Am J Surg Pathol       Date:  2011-06       Impact factor: 6.394

5.  IMP3 is a novel biomarker for adenocarcinoma in situ of the uterine cervix: an immunohistochemical study in comparison with p16(INK4a) expression.

Authors:  Cuizhen Li; Kenneth L Rock; Bruce A Woda; Zhong Jiang; Armando E Fraire; Karen Dresser
Journal:  Mod Pathol       Date:  2006-12-22       Impact factor: 7.842

Review 6.  Pancreatic intraepithelial neoplasia revisited and updated.

Authors:  B Sipos; S Frank; T Gress; S Hahn; G Klöppel
Journal:  Pancreatology       Date:  2008-12-12       Impact factor: 3.996

Review 7.  An illustrated consensus on the classification of pancreatic intraepithelial neoplasia and intraductal papillary mucinous neoplasms.

Authors:  Ralph H Hruban; Kyoichi Takaori; David S Klimstra; N Volkan Adsay; Jorge Albores-Saavedra; Andrew V Biankin; Sandra A Biankin; Carolyn Compton; Noriyoshi Fukushima; Toru Furukawa; Michael Goggins; Yo Kato; Gunter Klöppel; Daniel S Longnecker; Jutta Lüttges; Anirban Maitra; G Johan A Offerhaus; Michio Shimizu; Suguru Yonezawa
Journal:  Am J Surg Pathol       Date:  2004-08       Impact factor: 6.394

8.  The oncofetal protein IMP3: a novel biomarker for endometrial serous carcinoma.

Authors:  Wenxin Zheng; Xiaofang Yi; Oluwole Fadare; Sharon X Liang; Maritza Martel; Peter E Schwartz; Zhong Jiang
Journal:  Am J Surg Pathol       Date:  2008-02       Impact factor: 6.394

9.  Extrapulmonary small cell carcinomas express K homology domain containing protein overexpressed in cancer, but carcinoid tumors do not.

Authors:  Rochelle Simon; Patricia A Bourne; Qi Yang; Betsy O Spaulding; Paul A di Sant'Agnese; Hanlin L Wang; Haodong Xu
Journal:  Hum Pathol       Date:  2007-05-22       Impact factor: 3.466

10.  External validation of IMP3 expression as an independent prognostic marker for metastatic progression and death for patients with clear cell renal cell carcinoma.

Authors:  Nathan E Hoffmann; Yuri Sheinin; Christine M Lohse; Alexander S Parker; Bradley C Leibovich; Zhong Jiang; Eugene D Kwon
Journal:  Cancer       Date:  2008-04-01       Impact factor: 6.860

View more
  4 in total

Review 1.  Current Pathology Model of Pancreatic Cancer.

Authors:  Krzysztof Szymoński; Katarzyna Milian-Ciesielska; Ewelina Lipiec; Dariusz Adamek
Journal:  Cancers (Basel)       Date:  2022-05-07       Impact factor: 6.575

2.  Prognostic value of high IMP3 expression in solid tumors: a meta-analysis.

Authors:  Luyao Chen; Yongpeng Xie; Xintao Li; Liangyou Gu; Yu Gao; Lu Tang; Jianwen Chen; Xu Zhang
Journal:  Onco Targets Ther       Date:  2017-06-06       Impact factor: 4.147

Review 3.  IGF2BP3 From Physiology to Cancer: Novel Discoveries, Unsolved Issues, and Future Perspectives.

Authors:  Caterina Mancarella; Katia Scotlandi
Journal:  Front Cell Dev Biol       Date:  2020-01-15

Review 4.  The Emerging Role of RNA N6-Methyladenosine Modification in Pancreatic Cancer.

Authors:  Xiaoge Hu; Xiangxiang Lei; Jinhui Guo; Wen Fu; Wen Sun; Qiliang Lu; Wei Su; Qiuran Xu; Kangsheng Tu
Journal:  Front Oncol       Date:  2022-07-22       Impact factor: 5.738

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.